[1] IRANSHAHI M, REZAEE R, PARHIZ H, et al.Protective effects of flavonoids against microbes and toxins: the cases of hesperidin and hesperetin[J]. Life Sciences, 2015, 137: 125-132. [2] LI R, CAI L, XIE XF, et al.7,3'-dimethoxy hesperetin inhibits inflammation by inducing synovial apoptosisin rats with adjuvant-induced arthritis[J]. Immunopharmacology & Immunotoxicology, 2013, 35(1): 139-146. [3] PARHIZ H, ROOHBAKHSH A, SOLTANI F, et al.Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin:an updated review of their molecular mechanisms and experimental models[J]. Phytotherapy Research Ptr, 2015, 29(3): 323-331. [4] LI L, REN ZX, ZHAO P, et al.Research progress in antitumor pharmacological activities of hesperidin and hesperetin[J]. Acta Chinese Medicine(中医学报), 2018, 33(12): 2304-2308. [5] MIWA Y, MITSUZUMI H, SUNAYAMA T, et al.Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality[J]. Journal of Nutritional Science & Vitaminology, 2005, 51(6): 460-470. [6] KHAN A, IKRAM M, HAHMJR, et al. Antioxidant and anti-inflammatory effects of citrus flavonoid hesperetin: special focus on neurological disorders[J]. Antioxidants, 2020, 9(7): 609-614. [7] MULVIHILL EE, BURKE AC, HUFF MW.Citrus Flavonoids as regulators of lipoprotein metabolism and atherosclerosis[J]. Annual Review of Nutrition, 2016, 36(1): 275-299. [8] LI S, SHAO L, FANG J, et al.Hesperetin attenuates silica induced lung injury by reducing oxidative damage and inflammatory response[J]. Experimental and Therapeutic Medicine, 2021, 21(4): 297-308. [9] KONG R, WANG N, LUO H, et al.Hesperetin mitigates bile duct ligation-induced liver fibrosis by inhibiting extracellular matrix and cell apoptosis via the TGF-beta1/Smad Pathway[J]. Current Molecular Medicine, 2018, 18(1): 15-24. [10] CHOI D, KIM CL, KIM J E, et al.Hesperetin inhibit EMT in TGF-beta treated podocyte by regulation of mTOR pathway[J]. Biochemical and Biophysical Research Communications, 2020, 528(1): 154-159. [11] WANG B, LI LH, JIN P, et al.Hesperetin protects against inflammatory response and cardiac fibrosis in postmyocardial infarction mice by inhibiting nuclear factor kappaB signaling pathway[J]. Experimental and Therapeutic Medicine, 2017, 14(3): 2255-2260. [12] HENDERSON NC, RIEDER F, WYNN TA.Fibrosis: from mechanisms to medicines[J].Nature, 2020, 587(7835): 555-566. [13] ZEISBERG M, KALLURI R.Cellular Mechanisms of Tissue Fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis[J]. American Journal of Physiology Cell Physiology, 2013 304(3): 216-225. [14] RAGHU G, ROCHWERG B, ZHANG Y, et al.An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2015, 192(2): e3-e19. [15] ROBALO-CORDEIRO C, MORAIS A.Translating Idiopathic pulmonary fibrosis guidelines into clinical practice[J]. Pulmonology, 2021, 27(1): 7-13. [16] SUBBIAH R, RAJAGURU P, SUDHAKAR G.MicroRNAs as potential targets for progressive pulmonary fibrosis[J]. Front Pharmacol, 2015, 11(6): 254-269. [17] DAVID JL, FERNANDO JM.Idiopathic pulmonary fibrosis[J]. The New England Journal of Medicine, 2020, 378(19): 1811-1823. [18] NOBLE PW, ALBERA C, BRADFORD WZ, et al.Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials[J]. The Lancet, 2011, 377(9779): 1760-1769. [19] WOLLIN L, WEX E, PAUTSCH A.et al.Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis[J]. The European Respiratory Journal, 2015, 45(5): 1434-1445. [20] DUAN ZL, ZHOU R.Research progress of NF-κB in lung cancer[J]. Joural of Clinical and Pathological Research(临床与病理杂志), 2016, 36(3): 337-341. [21] MA H, FENG X, DING S.Hesperetin attenuates ventilator-induced acute lung injury through inhibition of NF-kappaB-mediatedinflammation[J]. European Journal of Pharmacology, 2015, 11(769): 333-341. [22] POLAT FR, DURAN Y, KARABOGA I, et al.Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury in a rat model[J]. Turkish Journal of Thoracic and Cardiovascular Surgery, 2020, 28(2): 359-368. [23] PARK JH, KU HJ, PARK JW.Hesperetin mitigates acrolein-induced apoptosis in lung cells in vitro and in vivo[J]. Redox Report: Communications in Free Radical Research, 2018, 23(1): 188-193. [24] JIANG Y, CHEN YQ, ZHANG J, et al.Antagonism of hesperidin to paraquat- induced oxidative stress in lung of rats[J]. Journal of Environment and Health(环境与健康杂志), 2018, 35(2): 133-137. [25] REN Z, SHEN J, MEI X, et al.Hesperidin inhibits the epithelial to mesenchymal transition induced by transforming growth factor-β1 in A549 cells through Smad signaling in the cytoplasm[J]. Brazilian Journal of Pharmaceutical Sciences, 2019, 55(e18172): 1-9. [26] MA QL, ZHANG LT, YANG WK, et al.Advances in the development of severe acute respiratory syndrome coronavirus 2 cell receptor ACE2[J]. Journal of Lanzhou Universit(兰州大学学报), 2020, 46(2): 70-75. [27] LIN CW, TSAI FJ, TSAI CH, et al.Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds[J]. Antiviral Res. 2005, 68(1): 36-42. [28] National Health Commission of the People's Republic of China.Notice on the Issuance of the Fifth trial version of the Diagnosis and Treatment Protocol for novel Coronavirus Pneumonia[EB/OL].(2020-02-04)[2021-08-09] http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml. [29] HUANG C, WANG Y, REN L, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. The Lancet, 2020, 395(10223): 497-506. [30] FAUCI AS, LANE HC, REDFIELD RR, et al.COVID-19 - Navigating the Uncharted[J]. The New England journal of medicine, 2020, 382(13): 1268-1269. [31] CHEN N, ZHOU M, DONG X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. The Lancet,2020, 395(10223): 507-513. [32] ARSHAD ALI S, BALOCH M, AHMED N, et al.The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat[J]. Journal of Infection and Public Health,2020, 13(4): 644-646. [33] KOYAMA Y, XUJ, LIU X, et al.New Developments on the Treatment of Liver Fibrosis[J]. Digestive Diseases, 2016, 34(5): 589-596. [34] ZHANG CY, YUAN WG, HE P, et al.Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets[J].World J Gastroenterol, 2016, 22(48): 10512-10522. [35] SHENG CL.Protective effect of 8-methylene-tert-butylamine hesperetin (MTBH)on CCl4-induced liver fibrosis in mice and its pharmacokinetic studies in rats[D]. Anhui Medical University, 2016. [36] LI WX.Effects and mechanisms of Hesperitin derivative-11 on CCl4-induced rat hepatic fibrosis[D]. Anhui Medical University, 2017. [37] CHEN X,DING HW, LI HD, et al.Hesperetin derivative-14 alleviates inflammation by activating PPAR-gamma in mice with CCl4-induced acute liver injury and LPS-treated RAW264.7 cells[J]. Toxicol Lett, 2017, 5(274): 51-63. [38] ZHENG Y, ZHANG YL, ZENG L I, et al.Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice[J]. European Journal of Medicinal Chemistry, 2021, 3(213): 162-173. [39] CHEN X, LI X F, CHEN Y, et al.Hesperetin derivative attenuates CCl4-induced hepatic fibrosis and inflammation by Gli-1-dependent mechanisms[J]. International Immunopharmacology, 2019, 76: 105838. [40] ELSHAZLY SM, MAHMOUD A.Antifibrotic activity of hesperidin against dimethylnitrosamine-induced liver fibrosis in rats[J]. Archiv für Experimentelle Pathologie und Pharmakologie, 2014, 387(6): 559-567. [41] PÉREZ-VARGAS JE, ZARCO N, SHIBAYAMA M, et al. Hesperidin prevents liver fibrosis in rats by decreasing the expression of nuclear factor-kappaB, transforming growth factor-beta and connective tissue growth factor[J]. Pharmacology, 2014, 94(1): 80-89. [42] WU F, JIANG L, HE X, et al.Effect of hesperidin on TGF-beta1/Smad signaling pathway in HSC[J]. China Journal of Chinese Materia Medica, 2015, 40(13): 2639-2643. [43] LIN X, KONG LN, HUANG C, et al.Hesperetin derivative-7 inhibits PDGF-BB-induced hepatic stellate cell activation and proliferation by targeting Wnt/beta-catenin pathway[J]. International Immunopharmacology, 2015, 25(2): 311-320. [44] QIU M, LI J, TAN L, et al.Targeted ablation of distal cerebrospinal fluid-contacting nucleus alleviates renal fibrosis in chronic kidney disease[J]. Frontiers in Physiology, 2018, 9(9): 1640-1650. [45] KALLURI R, WEINBERG RA.The basics of epithelial-mesenchymal transition[J]. Journal of Clinical Investigation, 2015, 119(6): 1420-142. [46] WANG HW, SHI L, XU YP, et al.Hesperetin alleviates renal interstitial fibrosis by inhibiting tubular epithelial-mesenchymal transition in vivo and in vitro[J]. Experimental & Therapeutic Medicine, 2017, 14(4): 3713-3719. [47] YANG XL, QU H Y, RONG JF, et al.Research progress in pathogenesis of myocardial fibrosis[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease(中西医结合心脑血管病杂志), 2020, 18(14): 2255-2258. [48] YIN Y, XU Y, MA H, et al.Hesperetin ameliorates cardiac inflammation and cardiac fibrosis in streptozotocin-induced diabetic rats by inhibiting NF-kappa B signaling pathway[J]. Biomedical Research-India, 2017, 28(1): 223-229. [49] VELUSAMY P, MOHANT, RAVI DB, et al.Targeting the Nrf2/ARE signalling pathway to mitigate isoproterenol-induced cardiac hypertrophy: plausible role of hesperetin in redox homeostasis[J]. Oxidative Medicine and Cellular Longevity, 2020, (9568278): 1-13. [50] DENG W, JIANG D, FANG Y, et al.Hesperetin protects against cardiac remodelling induced by pressure overload in mice[J]. Journal of Molecular Histology, 2013, 44(5): 575-585. [51] YANG Z, LIU Y, DENG W, et al.Hesperetin attenuates mitochondria-dependent apoptosis in lipopolysaccharide-induced H9C2 cardiomyocytes[J]. Molecular Medicine Reports, 2014, 9(5): 1941-1946. |